{"id":"foradil-aerolizer-low-dose","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Cough"},{"rate":"5-10%","effect":"Dysphonia"},{"rate":"5-10%","effect":"Headache"},{"rate":"5-10%","effect":"Nausea"},{"rate":"5-10%","effect":"Tremors"}]},"_chembl":{"chemblId":"CHEMBL2108580","moleculeType":"Unknown"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"This is achieved by stimulating the beta2-adrenergic receptors in the smooth muscle of the bronchial tubes, leading to bronchodilation and improved airflow. This mechanism is particularly beneficial for patients with chronic obstructive pulmonary disease (COPD) or asthma.","oneSentence":"Foradil Aerolizer, a low-dose form of the drug, is a long-acting beta2-adrenergic receptor agonist that helps to open airways in the lungs.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T03:32:34.628Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic obstructive pulmonary disease (COPD) for bronchodilation and improved lung function"}]},"trialDetails":[{"nctId":"NCT00383552","phase":"PHASE3","title":"Effects of Mometasone Furoate/Formoterol Combination Versus Mometasone Furoate Alone in Persistent Asthmatics (Study P04073AM1)(COMPLETED)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2006-09","conditions":"Asthma","enrollment":746},{"nctId":"NCT01641081","phase":"PHASE2","title":"Efficacy and Safety Study to Compare Formoterol Fumerate in the Pressair DPI to the Foradil Aerolizer in Patient With Mild to Moderate Asthma","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2012-06","conditions":"Asthma","enrollment":174},{"nctId":"NCT00932646","phase":"PHASE3","title":"Characterisation of 24-hour FEV1-time Profiles of Inhaled BI 1744 CL and Inhaled Foradil in Patients With Chronic Obstructive Pulmonary Disease","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2009-06","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":100},{"nctId":"NCT00931385","phase":"PHASE3","title":"Characterization of 24 Hour Spirometry Profiles of Inhaled BI 1744 CL and Inhaled Foradil in Patients With Chronic Obstructive Pulmonary Disease","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2009-06","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":99},{"nctId":"NCT00793624","phase":"PHASE3","title":"Safety and Efficacy of BI 1744 CL in Patients With Chronic Obstructive Pulmonary Disease I","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2009-02","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":906},{"nctId":"NCT00796653","phase":"PHASE3","title":"Safety and Efficacy of BI 1744 CL in Patients With Chronic Obstructive Pulmonary Disease II","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2009-01","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":937},{"nctId":"NCT01013753","phase":"PHASE2","title":"A Study of the Safety and Efficacy of 4 Doses of BI 1744 CL Delivered Via the Respimat in Patients With Asthma.","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2010-02","conditions":"Asthma","enrollment":198}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Formoterol"],"phase":"phase_2","status":"active","brandName":"Foradil Aerolizer, Low Dose","genericName":"Foradil Aerolizer, Low Dose","companyName":"AstraZeneca","companyId":"astrazeneca","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Foradil Aerolizer, a low-dose form of the drug, is a long-acting beta2-adrenergic receptor agonist that helps to open airways in the lungs. Used for Chronic obstructive pulmonary disease (COPD) for bronchodilation and improved lung function.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}